Innate Pharma SA
Arnaud Dujardin has extensive experience in research and development, currently serving as an Ingénieur recherche et développement at Innate Pharma since March 2010. Prior to this role, Arnaud Dujardin worked as an Ingénieur d'étude at the Institute of Pharmacology and Structural Biology (CNRS) from 2006 to February 2010 and gained initial experience as a Stagiaire DEA at INSERM in 2003-2004. Arnaud Dujardin holds a DEA degree in Immunologie from Université Paul Sabatier Toulouse III.
This person is not in any teams
This person is not in any offices
Innate Pharma SA
2 followers
Innate Pharma SA is a France-based biopharmaceutical Company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The Company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk.